Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Mar 11, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a virtual program called SHAReClinic, which aims to help men with prostate cancer and their partners improve their sexual health and intimacy after treatment. The SHAReClinic offers online education and counseling to support patients through their recovery journey. The goal is to see if this virtual support can effectively enhance sexual function and satisfaction for those affected by prostate cancer.
To participate in this study, individuals need to be 18 years or older and either be starting treatment for localized prostate cancer (like surgery or radiation), currently undergoing treatment, or have completed treatment within the last six months. Participants will have access to helpful resources online and will be guided through various stages of recovery. It's important to know that the trial is only open to men who can use a computer or smartphone with internet access and who meet certain health criteria. By taking part in this trial, participants can help shape future care for sexual health in prostate cancer survivors across Canada.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patients who are scheduled for first-line treatment for localized prostate cancer, either through radical prostatectomy (open or robotic) or radiation treatment (brachytherapy, external beam) Alone, or with adjuvant Androgen Deprivation Therapy (ADT) OR
- • Patients currently undergoing active treatment for prostate cancer OR
- • Patients who have undergone cancer treatment in the past 6 months
- • Patients who are hormone and/or chemotherapy-naïve
- • Patients who have access to a computer or smartphone with internet access
- • Patients who are 18 years of age or older
- Exclusion Criteria:
- • Patients on ADT alone as primary treatment, and/or patients on chemotherapy
- • Patients who lack English proficiency
- • Patients on nitrate therapy or have other contra-indications to phosphodiesterase type 5 inhibitors (PDE5i's)
- • Patients with medical conditions that would preclude safe sexual activity
- • Patients who have had previous treatment for PCa
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saskatoon, Saskatchewan, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
Barrie, Ontario, Canada
Toronto, Ontario, Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
Edmonton, Ontario, Canada
Mississauga, Ontario, Canada
Ottawa, Ontario, Canada
Patients applied
Trial Officials
Andrew Matthew, PhD. C.Psych
Principal Investigator
Princess Margaret Cancer Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported